HuagongsheHuagongshe Chemistry Print Report · For research reference only
HCID 58169323, compound → HCID 58169323, compound
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | HCID 58169323 | HCID 58169323 | — |
| Reactant | HCID 58169431 | HCID 58169431 | — |
| Product | HCID 58169323 | HCID 58169323 | — |
| Product | HCID 58169431 | HCID 58169431 | — |
| Product | HCID 58169468 | HCID 58169468 | — |
Reaction Steps
(S)-1-(5-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyrimidin-2-yl)thiophen-2yl)ethanol (Compound 144) (80 mg) and (R)-1-(5-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyrimidin-2-yl)thiophen-2-yl)ethanol (Compound 147) (75 mg) were obtained by Prep-Chiral-HPLC from the above racemic 1-(5-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyrimidin-2-yl)thiophen-2-yl)ethanol (350 mg). The stereostructure of and (R)-1-(5-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyrimidin-2-yl)thiophen-2-yl)ethanol (Compound 147) was confirmed by the comparable sample prepared from 1-(5-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyrimidin-2-yl)thiophen-2-yl)ethanone with BH3/S-CBS-Me. Synthetic procedures described as following:
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US09422271B2 |
| Source dataset | uspto-grants-2016_08 |
| ORD ID | ord-41c815e98cbe4ef49ce3d83057ce3615 |
| Source note | uspto-grants-2016_08 |